Bicycle Therapeutics, a Cambridge, UK-based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, has been awarded a grant from Innovate UK, the UK’s innovation agency.
The grant will allow Bicycle technology to develop the next generation of novel antibiotics.
Led by Kevin Lee, Ph.D., Chief Executive Officer, Bicycle Therapeutics is developing a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need.
FinSMEs
04/01/2018